<DOC>
	<DOCNO>NCT00287547</DOCNO>
	<brief_summary>The purpose study assess safety , pharmacokinetics clinical activity immunogenicity BMS-188667 ( CTLA4Ig ) subject psoriasis vulgaris</brief_summary>
	<brief_title>Phase II Randomized , Double-Blind , Placebo-Controlled Study BMS-188667 ( CTLA4Ig ) Patients With Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Diagnosis documentation history stable psoriasis vulgaris least 6 month duration . vulgaris total body surfae area involvement least 10 % Failure toxicity and/or inefficacy least one standard anti psoriatic therapy include topical treatment , phototherapy , photochemotherapy , methotrexate , cyclosporin A etretinate . Male female subject willing receive adequate counseling exercise adequate contraceptive measure enrolle study . Functional class ( V ( ACR ) RA amyloidosis ) Active vasculitis ( except subcutaneous rheumatoid nodule ) . Subjects history asthma , angioedema anaphylaxis . Subjects evidence active latent bacterial viral invedtions . Subjects history malignancy ( except basal cell superficial squamous cell skin carcinoma ) . body weight &gt; 100 kg ( 220 lb . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>